Fenebrutinib in H(1) antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial

Bruton’s tyrosine kinase (BTK) is crucial for FcεRI-mediated mast cell activation and essential for autoantibody production by B cells in chronic spontaneous urticaria (CSU). Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU. This doubl...

Descripción completa

Detalles Bibliográficos
Autores principales: Metz, Martin, Sussman, Gordon, Gagnon, Rémi, Staubach, Petra, Tanus, Tonny, Yang, William H., Lim, Jeremy J., Clarke, Holly J., Galanter, Joshua, Chinn, Leslie W., Chu, Tom, Teterina, Anastasia, Burgess, Tracy, Haddon, D. James, Lu, Timothy T., Maurer, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604722/
https://www.ncbi.nlm.nih.gov/pubmed/34750553
http://dx.doi.org/10.1038/s41591-021-01537-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604722/
https://www.ncbi.nlm.nih.gov/pubmed/34750553
http://dx.doi.org/10.1038/s41591-021-01537-w

Ejemplares similares